(1) 上海市人才局, 白玉兰人才计划浦江项目, 25PJD138, 静磁协同增强肿瘤治疗电场抑制脑胶质瘤增殖的机理及调控方法研究, 2025-12 至 2027-11, 30万元, 在研, 主持 

(2) 同济大学附属第四人民医院, 人才引进科研启动专项, SYKYQD10101, 电磁复合场在脑胶质瘤中的作用及机制研究, 2024-01 至 2027-12, 30万元, 在研, 主持 

(3) 江苏省科技厅, 青年基金, SBK2024041256, 静磁协同增强中频低强度电场肿瘤抑制效应的机理及调控, 2024-07 至 2027-06, 20万元, 在研, 主要参与人员 

(4) 同济大学附属第四人民医院, 学科助推计划, SY-XKZT -2023-1008, 电磁谐振抑制脑胶质瘤细胞增殖的方法及其生物物理机制研究, 2024-03 至 2027-02, 10万元, 在研, 主要参与人员

(5) 上海市虹口区卫生健康委员会, 面上项目, 虹卫2402-07 , 人骨髓来源间充质干细胞治疗航空辐射致骨髓毒性的作用及机制研究 , 2024-10 至 2026-09, 6万元, 在研, 主持

(6) 上海市虹口区卫生健康委员会, 面上项目, 虹卫2402-09, ZFP 468/TFAM轴调控下的线粒体功能对乳腺癌X线放疗敏感性的作用及机制研究, 2024-10 至 2026-09, 6万元, 在研, 主要参与人员 

(7) 同济大学附属第四人民医院, 学科助推计划, SY-XKZT-2019-3007 , 人才助推项目, 2019-11 至 2024-12, 10万元, 结题, 主持

(8) 高能粒子对间充质干细胞的放射生物学研究, 欧洲航天局ESA CORA IBER, 40 万, 2019-10至2023-11, 结题, 主要参与人员（博士课题）

 Alexander Rühle, Dai Ping#, RamonLopez Perez, Maren Strack,Stephan Brons,Qin Yijia, Jürgen Debus, PatrickWuchter, Anca-Ligia Grosu, Peter E. Huber, Nils H. Nicolay. Human mesenchymalstromal cells maintain their stem cell traits after high-LET particleirradiation Potential implications for particle radiotherapy and manned spacemissions. Cancer Letters, 2022, 524: 172-181. (IF 10.1共同第一作者)

 XingLi,Kaida Liu, Haohan Fang, Zirong Liu, Yuchen Tang, Ping Dai.Electrodynamic Interaction between Tumor Treating Fields and MicrotubuleElectrophysiological Activities. APLBioeng, 2024,8(2): 026118. (IF 6.6唯一 通讯作者)

YanlingWang, Xiaoping Ma, Jia Ma, Jing Li, Zhiyi Lin, Wei Gao, Ping Gong, Ping Dai.Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy inadvanced lung cancer. BMC Cancer, 2025, 25(1): 791. (IF 3.4责任通讯作者)

KaidaLiu, Ping Dai#, Zirong Liu, Haohan Fang, Xing Li, Wei Gao.Comprehensive Simulations of Intracellular Electric Fields during Exposure toTumor Treating Fields (TTFields). Frontiers in Oncology, 2025, 15:1520504. (IF3.5 共同第一作者)

Xing Li,Kaida Liu, Haohan Fang, Rongzi Liu, Wei Gao, Ping Dai. A theoreticalstudy on evaluating brain tumor changes in tumor treating fields therapy byimpedance detection. Frontiers in Oncology, 2024, 1443406. (IF 3.5 责任通讯作者)

YanlingWang, Xiaoxuan Yang, Jia Ma, Ping Gong, Ping Dai; Thyroid dysfunction(TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer. Heliyon,2024, 10(5), e27077. (IF 4责任通讯作者)

Kaichun Li; Ping Dai; Jian Li; Long Liu; Shiyu Cheng;Qingliang Fang; Bingxiang Wu; AKT/FOXM1/STMN1signaling pathway activation by SMC1A promotes tumor growth in breast cancer, Thejournal of gene medicine, 2024, 26(1), e3661. (IF3.5参与作者)

Li, J.;Dai, P.; Sun,J.; Yu, W.;Han, W.; & Li, K.; FBP1 induced by β-elemene enhances thesensitivity of gefitinib in lung cancer. Thoracic cancer, 2023, 14(4),371–380. (IF 2.9参与作者)

Yu W, Wang Z, Dai P, Sun J, LiJ, Han W, Li K. The activation of SIRT1 by resveratrol reduces breast cancermetastasis to lung through inhibiting neutrophil extracellular traps. J DrugTarget. 2023 Dec;31(9):962-975. PMID: 37772906. (IF 4.5 参与作者)

 Li, K., Zhou, D., Cui, H., Mo, G.,Liu, Y., Zheng, K., Zhou, Z., Li, J., Dai, P., Sun, J., Zhang, Y., &Gao, J. Size-transformable gelatin/nanochitosan/doxorubicin nanoparticles withsequentially triggered drug release for anticancer therapy. Colloids andsurfaces. B, Biointerfaces, 2022,220, 112927. (IF 5.8参与作者)

 Li, K., Pang, L., Pan, X., Fan, S., Wang, X., Wang, Q., Dai, P.,Gao, W., & Gao, J., GE11 Modified PLGA/TPGS Nanoparticles TargetingDelivery of Salinomycin to Breast Cancer Cells. Technology in cancer research& treatment, 2021, 20, 15330338211004954. (IF 2.8参与作者)

 Ping Dai; Jing Li; Xiao-Ping Ma; Jian Huang; Juan-JuanMeng; Ping Gong; Efficacy and safety of COX-2 inhibitors for advancednon-small-cell lung cancer with chemotherapy: a meta-analysis,OncoTargets and Therapy, 2018, 11: 721-730 (IF4,第一作者 )

代平; 王于理; 王金辉; 林芷伊; 张珂; 徐丹; 巩平; 脾多肽对晚期卵巢癌化疗引起骨髓抑制影响,中华肿瘤防治杂志, 2018, 3(25): 437-441. (第一作者 )